Anti-epidermal growth factor receptor drugs in cancer therapy

Expert Opinion on Investigational Drugs

Volumn 11, Issue 6, 2002, Pages 755-768

  Ciardiello, Fortunato ^a   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Autocrine growth; Combination therapy; Epidermal growth factor receptor; Monoclonal antibodies; Signal transduction inhibitors; Small molecule tyosine kinase inhibitors

Indexed keywords

4 (3 CHLORO 4 FLUOROANILINO) 7 METHOXY 6 (3 MORPHOLINOPROPOXY) QUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EMD 55900; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; HR3; IMC 225; IMCLONE; IRINOTECAN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; Y 10; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ASTHENIA; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG CLEARANCE; DRUG DESIGN; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; FEVER; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; METABOLIC DISORDER; MOUSE; NAUSEA; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; THROMBOCYTOPENIA; UROGENITAL TRACT CANCER; ANIMAL; DRUG ANTAGONISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMAN; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPPORT, NON-U.S. GOV'T; ANIMALS; HUMANS;

EID: 0036016088     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.6.755     Document Type: Review

References (98)

1. Epidermal growth factor-related peptides and their receptors in human malignancies
2. The erbB family of receptors and their ligands: Multiple targets for therapy
3. The Type III epidermal growth factor receptor mutation
4. Enhanced epidermal growth factor receptor signalling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex)
5. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
6. Altered gene expression in drug-resistant human breast cancer cells
7. The epidermal growth factor receptor as a target for cancer therapy
8. Autocrine secretion and malignant transformation of cells
9. The EGF receptor family as targets for cancer therapy
10. Blockade of receptors for growth factors: An anticancer therapy
11. Antitumour effect of antiepidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well-established A431 cell xenografts
12. Antitumour effects of doxorubicin in combination with antiepidermal growth factor receptor monoclonal antibodies
13. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumour xenograft model
14. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
15. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells
16. Involvement of p27kip1 in G1 arrest mediated by an antiepidermal growth factor receptor monoclonal antibody
17. Antiepidermal growth factor receptor monoclonal antibody C225 upregulates p27kip1 and induces G1 arrest in prostatic cancer cell line DU145
18. Antitumour activity of combined blockade of epidermal growth factor receptor and protein kinase A
19. Antitumour activity of sequential treatment with topotecan and antiepidermal growth factor receptor monoclonal antibody C225
20. Mouse-human chimeric antiepidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice
21. Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
22. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
23. Antiangiogenic and antitumour activity of antiepidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
24. Paclitaxel enhances the effects of the antiepidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma
25. Combined modality therapy of A431 human epidermoid cancer using antiEGFr antibody C225 and radiation
26. In vivo enhancement of tumour radioresponse by C225 antiepidermal growth factor receptor antibody
27. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis and radiosensitivity in squamous cell carcinomas of the head and neck
28. Antitumour activity of combined treatment of human cancer cells with ionizing radiations and antiepidermal growth factor receptor monoclonal antibody C225 plus Type I protein kinase A antisense oligonucleotide
29. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics and tumour angiogenesis
30. Development of ABX-EGF, a fully human antiEGF receptor monoclonal antibody, for cancer therapy
31. Tumour necrosis factor a sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas as for antiEGFR therapy
32. Unarmed, tumour-specific monoclonal antibody effectively treats brain tumours
33. Growth suppression of intracranial xenografted glioblastomata overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor
34. Monoclonal antibody 806 the growth of tumour xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild type EGFR
35. A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections
36. Aquired resistance to the antitumour activity of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumour angiogenesis
37. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
38. Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor a expression in head and neck squamous carcinoma and inhibition by antiepidermal treatment
39. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer
40. Monoclonal antibody (MoAb) IMC-225, an antiepidermal growth factor receptor (EGFr), for patients (Pts) with EGFr-positive tumours refractory to or in relapse from previous therapeutic regimens
41. Phase II study of antiepidermal growth factor receptor (EGFr) antibody C225 alone in patients (pts) with metastatic renal cell carcinoma (RCC)
42. Phase I study of antiepidermal growth factor receptor antibody Cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
43. Phase II study of antiepidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer
44. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
45. Acne-like rash predicts response in patients treated with Cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
46. Efficacy and safety of the antiepidermal growth factor receptor antibody (EGFR) IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to chemotherapy
47. Clinical results: A fully human antiEGFr antibody in patients with advanced cancer
48. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor
49. Blockade of growth factor receptors in ductal carcinoma in situ of the breast inhibits epithelial proliferation
50. Antitumour activity of ZD1839 ('Iressa') in combination with cisplatin in NIH3T3 cells expressing human epidermal growth factor receptor
51. Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
52. kip1 inducing G1 arrest and enhancing the antitumour effect of interferon α
53. Low dose cisplatin can modulate the sensitivity of human non-small cell lung carcinoma cells to EGFR tyrosine kinase inhibitor (ZD1839; 'Iressa') in vivo
54. Signalling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors
55. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
56. ZD1839 ('Iressa'), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multi-drug resistant MCF-7 ADR human breast cancer cells
57. ZD1839 (Iressa), an EGFR-TKI, potentiates radiation/chemotherapy cytotoxicity in human non-small cell lung cancer (NSCLC) cell lines
58. An evaluation of the EGFR tyrosine kinase inhibitor ZD1839 (Iressa) in combination with ionising radiation
59. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
60. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
61. Inhibition by ZD1839 (Iressa) of epidermal growth factor (EGF) and heregulin induced signalling pathways in human breast cancer cells
62. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signalling and suppresses the growth of HER2-overexpressing tumour cells
63. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
64. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumour effects in athymic mice
65. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitors
66. Radiosensitization of human breast cancer cells by a novel erbB family receptor tyrosine kinase inhibitor
67. Preclinical profile of PKI-166, a novel and potent EGFR tyrosine kinase inhibitor for clinical development
68. Blockade of the epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
69. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer
70. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW-2016, on the growth of human normal and tumour-derived cell lines in vitro and in vivo
71. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 ('Iressa'), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)
72. A Phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with solid malignant tumours
73. Intermittent oral ZD1839 ('Iressa'), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a Phase I Study
74. Continuous administration of ZD1839 ('Iressa'), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumour types: Evidence of activity and good tolerability
75. Final results of the dose-escalation phase of a Phase I, dose-escalation, pharmacokinetics (PK) and pharmacodynamics study of ZD1839: NCIC CTG IND.122
76. Pharmacoldynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
77. Initial results from a Phase II trial of ZD1839 (Iressa) as second- and third-line monotherapy for patients with advanced nonsmall-cell lung cancer (IDEAL 1)
78. Pilot trial of ZD1839 ('Iressa'), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer (NSCLC)
79. A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C and paclitaxel (P) in previously lung cancer (NSLC)
80. Combination therapy with ZD1839 (Iressa), an orally-active, selective, epidermal growth factor receptor tyrosine inhibitor (EGFR-TKI), gemcitabine and cisplatin, in patients with advanced solid tumours: On tolerability, efficacy and pharmacokinetics
81. Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin in patients with cancer (aCRC)
82. A Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumours
83. Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774: A Phase I and pharmacokinetic (PK) study
84. Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumours
85. Phase i and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
86. Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck
87. Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma
88. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)
89. A Phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumours
90. A Phase I and pharmacokinetic study of CI-1033, a panerbB tyrosine kinase inhibitor, given orally on days 1, 8 and 15 every 28 days to patients with solid tumours
91. A Phase I clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, CI-1033, in patients with solid tumours
92. ZD1839 (Iressa), a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signalling in HER2 cancer cells
93. Epidermal growth factor receptor family and chemosensitization
94. On receptor inhibitors and chemotherapy
95. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
96. Insulin-like growth factor receptor I mediates resistance to antiepidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signalling
97. Cooperative inhibition of renal cancer growth by antiepideraml growth factor receptor antibody and protein kinase A antisense oligonucleotide
98. Eradication of established tumours by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy